Fr
About
World Leader in Cell Expansion & Rejuvenation
Commercial
Clinical
Preclinical
Contact us
Fr
About
LEADERSHIP
Team
Contact us

Guy Sauvageau

M.D., Ph.D, FRCP(C)

Co-Chief Executive Officer

Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.

David Millette

CA, CPA, CFA, Lawyer

Co-Chief Executive and Chief Operating Officer

Over 20 years of experience in business management and advisory services. Broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare.

Pierre Caudrelier

M.D.

Chief Medical Officer

Over 30 years of experience in various positions in the Pharma and Biotech sectors. He has published 21 articles and is inventor or co-inventor on 19 patents from 2 patent families.

Isabelle Martin

CPA, MBA

VP Finance

Over 20 years of experience in business management and finance. Broad range of complex business models through 15 years of experience as VP of Finance in major international manufacturing groups based in Europe and Canada, including Automotive, Paper, Plastics and Banking industries.

Fr
About
LEADERSHIP
Team
Contact us

Jean Proulx

M.Sc., MBA

VP Medical and Scientific Affairs

25 years of experience in the pharmaceutical industry. Previously engaged in R&D, registration and commercialization of innovative treatments for cardiovascular, venous diseases and oncology at Servier.

Nathalie Bourgouin

M.Sc.

VP Quality and Compliance

Over 30 years of experience in quality and compliance in Pharmaceuticals and Biotech. She was VP Compliance at Skillpad and Senior Director Global Clinical and Regulatory Affairs Compliance at Aptalis. Her expertise is developing compliant risk-based quality assurance processes.

Fr
About
Board of
Directors
Contact us

Michael May

Chairman of the Board, ExCellThera

President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM).

Elizabeth Douville

Director

President and CEO of IRICoR, a Center of Excellence in Commercialization and Research specializing in drug discovery in oncology and related areas, based at IRIC/University of Montreal.

Michael Hanley

Director

Corporate director with 25+ years of experience in senior management roles and corporate governance; Lead Director, Nuvei; Director, LyondellBasell

Guy Sauvageau

Co-Chief Executive Officer

Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.

Fr
About
Board of
Directors
Contact us

Richard Cherney

Director

Managing Partner at Davies Ward Phillips & Vineberg. 35+ years of experience as legal partner to Canadian public and private companies . Has served as a director of several public companies.

Anne Marinier

Co-Founder

25+ years of experience in medicinal chemistry . Co-founded and led IRIC’s Drug Discovery Unit, and identified UM171. Previously Group Leader in the Drug Discovery Research group at Bristol-Myers Squibb.

David Millette

CA, CPA, CFA, Lawyer

Co-Chief Executive and Chief Operating Officer

Over 20 years of experience in business management and advisory services. Broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare.

Fr
About
Scientific
Advisory Board
Contact us

Peter Zandstra

Ph.D., FRSC(E)

Co-founded three biotech companies, including ExCellThera and Notch Therapeutics

Director and Professor at UBC’s Michael Smith Laboratories Internationally recognized cell engineering expert.

Steve Woodside

Ph.D.

Senior Director, Engineering at Notch Therapeutics

Previously held senior development positions at STEMCELL Technologies. 20+ years of experience in science and technology R&D.

Andromachi (Machi) Scaradavou

M.D.

Transplant Physician at Memorial Sloan-Kettering Cancer Center

Pediatric hematologist and oncologist with extensive experience in bone marrow transplants.

Keith Humphries

M.D., Ph.D., FRCP(C)

Part of the BC Cancer Agency for 30 years. Major research interests include Gene Therapy by targeting hematopoietic stem cells with special emphasis on hemoglobinopathies.

Bernhard Gentner

M.D.

Group leader, Translational Stem Cell and Leukaemia Unit at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)

Group leader, Translational Stem Cell and Leukaemia Unit at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)